| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
Cell lines | NALM-6 cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reaction Conditions | 0.1 nM ~ 10 μM; 24 hrs |
Applications | In NALM-6 cells, Idarubicin inhibited cell proliferation with an IC50 value of 12 nM. |
Animal models | Rats, rabbits, mice and dogs |
Dosage form | 2 mg/kg, 0 mg/kg ~ 75 mg/kg, 3 mg/kg and 0 mg/kg ~ 75 mg/kg; i.v. |
Applications | Reduction of Idarubicin was dependent upon ketone reductases, and proceeds more stereoselectivity than that of most ketones. The high stereospecificity in Idarubicin reduction might be attributed to chiral induction under the presence of asymmetric centres near to the carbonyl group in Idarubicin. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | Idarubicin is an inhibitor of DNA topoisomerase II [1]. Idarubicin is a synthetic anthracycline anticancer drug widely used in the treatment of acute myelogenous leukemia and some other hematological malignancies. It can be bioactivated by NADPH-cytochrome P450 reductase with resulting formation of single-strand breaks in DNA. This is the mechanism of Idarubicin ‘s antitumor effect [2]. Idarubicin is developed in an attempt to reduce the cardiotoxicity and enhance the therapeutic efficacy of the parent compound. Unlike the parent compound, Idarubicin can be given orally and has a better therapeutic index with respect to cardiotoxicity. Idarubicin has been shown to be an effective anti-leukemic agent in children and adults [3]. References: |
m.cnreagent.com